|
US10100316B2
(en)
*
|
2002-11-21 |
2018-10-16 |
Archemix Llc |
Aptamers comprising CPG motifs
|
|
WO2004081021A2
(en)
*
|
2003-03-12 |
2004-09-23 |
Duke University |
Oligonucleotide mimetics
|
|
US7674456B2
(en)
*
|
2004-06-14 |
2010-03-09 |
Charles Wiseman |
Breast cancer cell lines and uses thereof
|
|
AU2006218115B2
(en)
|
2005-02-23 |
2012-08-02 |
Bavarian Nordic A/S |
Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents
|
|
JP2009500412A
(ja)
*
|
2005-07-07 |
2009-01-08 |
コーリー ファーマシューティカル グループ，インコーポレイテッド |
癌の処置のための、抗ｃｔｌａ−４抗体とｃｐｇモチーフ含有合成オリゴデオキシヌクレオチドとの組み合わせ治療
|
|
CN1919873B
(zh)
*
|
2005-08-25 |
2012-05-30 |
北京沙东生物技术有限公司 |
包含人HSP70 ATPase结构域与哺乳动物p53蛋白的融合蛋白及其应用
|
|
JP6092497B2
(ja)
*
|
2006-03-30 |
2017-03-08 |
ユニバーシティー オブ カリフォルニア |
抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
|
|
BRPI0811228A2
(pt)
*
|
2007-05-24 |
2014-10-21 |
Glaxonsmithkline Biolog S A |
Composição liofilizada, e, métodos para produzir uma composição liofilizada e para produzir uma composição imunológica.
|
|
US7998488B2
(en)
*
|
2008-11-14 |
2011-08-16 |
Baxter International Inc. |
Vaccine formulations and uses thereof
|
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
EP3082853A2
(en)
*
|
2013-12-20 |
2016-10-26 |
The Broad Institute, Inc. |
Combination therapy with neoantigen vaccine
|
|
US10993997B2
(en)
|
2014-12-19 |
2021-05-04 |
The Broad Institute, Inc. |
Methods for profiling the t cell repertoire
|
|
US10975442B2
(en)
|
2014-12-19 |
2021-04-13 |
Massachusetts Institute Of Technology |
Molecular biomarkers for cancer immunotherapy
|
|
ES3011733T3
(en)
|
2015-02-13 |
2025-04-08 |
Transgene |
Immunotherapeutic vaccine and antibody combination therapy
|
|
EP4122492A1
(en)
|
2015-02-25 |
2023-01-25 |
Memorial Sloan Kettering Cancer Center |
Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
|
|
KR20180006916A
(ko)
*
|
2015-04-17 |
2018-01-19 |
메모리얼 슬로안-케터링 캔서 센터 |
고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
|
|
TW202523682A
(zh)
|
2015-05-20 |
2025-06-16 |
美商博德研究所有限公司 |
共有之gata3相關之腫瘤特異性新抗原
|
|
US20190038713A1
(en)
*
|
2015-11-07 |
2019-02-07 |
Multivir Inc. |
Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
|
JP7025339B2
(ja)
|
2016-02-25 |
2022-02-24 |
メモリアル スローン ケタリング キャンサー センター |
癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス
|
|
CN109152827B
(zh)
*
|
2016-02-25 |
2023-07-21 |
纪念斯隆凯特琳癌症中心 |
重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途
|
|
WO2018107011A1
(en)
*
|
2016-12-08 |
2018-06-14 |
City Of Hope |
P53-targeting vaccines and pd-1 pathway inhibitors and methods of use thereof
|
|
WO2018111902A1
(en)
|
2016-12-12 |
2018-06-21 |
Multivir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
|
WO2018112470A1
(en)
*
|
2016-12-16 |
2018-06-21 |
The Brigham And Women's Hospital, Inc. |
Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
|
|
WO2018140391A1
(en)
|
2017-01-24 |
2018-08-02 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
|
EP3621646A4
(en)
|
2017-05-12 |
2021-06-02 |
Memorial Sloan Kettering Cancer Center |
VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY
|
|
WO2019090343A1
(en)
*
|
2017-11-06 |
2019-05-09 |
Memorial Sloan Kettering Cancer Center |
Heat-inactivated vaccinia virus as a vaccine immune adjuvant
|
|
EP3768698B1
(en)
|
2018-03-19 |
2025-02-12 |
MultiVir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
|
|
BR112021004692A2
(pt)
|
2018-09-15 |
2021-06-08 |
Memorial Sloan Kettering Cancer Center |
poxvírus recombinantes para imunoterapia de câncer
|
|
US12274784B2
(en)
|
2018-10-12 |
2025-04-15 |
Synergene Therapeutics, Inc. |
Methods for reducing side effects of immunotherapy
|
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
|
US11938124B2
(en)
*
|
2020-06-24 |
2024-03-26 |
Pmv Pharmaceuticals, Inc. |
Combination therapy for treatment of cancer
|
|
CN115537399B
(zh)
*
|
2022-09-22 |
2025-02-11 |
沈阳药科大学 |
修饰化外泌体及其制法和外泌体联合pd-1抗体的原位喷雾水凝胶和应用
|